Person:
DALKILIÇ, HÜSEYİN EDİZ

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

DALKILIÇ

First Name

HÜSEYİN EDİZ

Name

Search Results

Now showing 1 - 10 of 90
  • Publication
    Interim analysis of baseline characteristics and preferences of administration route of rheumatoid arthritis patients who are bio-naive or switched between advanced ra treatments; a multicenter, prospective, observational study
    (Wiley, 2018-09-01) Direskeneli, Haner; Karadağ, Ömer; Ateş, Aşkın; Tufan, Abdurrahman; İnanç, Nevsun; Koca, Süleyman Serdar; Çetin, Gözde Yıldırım; Akar, Servet; Çınar, Muhammet; Yılmaz, Sedat; Yılmaz, Neslihan; Dalkılıç, Ediz; Beş, Cemal; Özbalkan, Zeynep; Yılmazer, Bariş; Şahin, Ali; Ersözlü, Emine Duygu; Tezcan, Mehmet Engin; Şen, Nesrin; Keser, Gökhan; Tansoker, İlkan; Hacıbedel, Fatma Başak; Helvacıoğlu, Kerem; Günay, Levent Mert; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; CMF-4757-2022
  • Publication
    Unintentional monotherapy in rheumatoid arthritis patients receiving tofacitinib and drug survival rate of tofacitinib
    (BMJ Publishing Group, 2022-06-01) İnanç, N.; Abacar, K.; Öztürk, M. A.; Tufan, A.; Karadeniz, H.; Sarı, I.; Can, G.; Erez, Y.; Pehlivan, Yavuz; Dalkılıç, Ediz; Ocak, Tuğba; Cefle, A.; Yazıcı, A.; Şenel, A.; Akar, S.; Ediboğlu, E. Durak; Koca, S. S.; Sağır, R. Pişkin; Yılmaz, S.; Gülcemal, S.; Gündüz, O. Soysal; Başıbüyük, C. S.; Alkan, S.; Cesur, T. Y.; Önen, F.; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; OCAK, TUĞBA; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; Romatoloji Bilim Dalı; FQP-0451-2022; JHC-5173-2023; FPQ-5941-2022
  • Publication
    Impact of obesity on drug survival of tofacitinib in patients with rheumatoid arthritis: Analysis from the Turkbio registry
    (Wiley, 2018-09-01) Babaoğlu, Hakan; Göker, Borna; İnanç, Nevsun; Birlik, Merih; Koca, Süleyman Serdar; Cefle, Ayşe; Dalkılıç, Ediz; Tufan, Abdurrahman; Yılmaz, Sema; Şenel, Soner; Akar, Servet; Akkoç, Nurullah; Önen, Fatoş; Gazel, Ummugülsüm; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; CMF-4757-2022
  • Publication
    A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting from Turkbio registry
    (Bmj Publishing Group, 2021-06-01) Yazici, A.; Isik, O. Ozdemir; Koca, S. S.; Senel, S.; Inanc, N.; Akar, S.; Yilmaz, S.; Gunduz, O. Soysal; Cefle, A.; Onen, F.; Dalkilic, E.; DALKILIÇ, HÜSEYİN EDİZ; Pehlivan, Y.; Tıp Fakültesi; 0000-0003-2167-4509; 0000-0002-3835-466X; 0000-0002-3734-1242; 0000-0002-6341-2622; JBI-6627-2023; AAT-3636-2020; HTP-6798-2023; AAA-8970-2021; HJY-2666-2023; JDV-5142-2023
  • Publication
    Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: Cross-sectional data from the psoriatic arthritis-international database
    (Clinical & Exper Rheumatology, 2021-05-01) Bilgin, E.; Aydin, S. Z.; Tinazzi, I.; Bayindir, O.; Kimyon, G.; Ozisler, C.; Dogru, A.; ; Aksu, K.; Cetin, G. Yildirim; Yilmaz, S.; Solmaz, D.; Omma, A.; Can, M.; Kucuksahin, O.; Yavuz, S.; Ersozlu, E. D.; Kilic, L.; Tarhan, E. F.; Tufan, M. Aydin; Akyol, L.; Cinar, M.; Erden, A.; Gonullu, E.; Yildiz, F.; Bakirci, S.; Erbasan, F.; Esmen, S. Ergulu; Kucuk, A.; Tufan, A.; Balkarli, A.; Mercan, R.; Erten, S.; Akar, S.; Kasifoglu, T.; Duruoz, T.; Yazisiz, V.; Kalyoncu, U.; Dalkılıç, E.; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; Romatoloji Ana Bilim Dalı
    ObjectiveTo explore the impact of early versus late-onset psoriasis (PsO) on the disease characteristics of psoriatic arthritis (PsA) in a large-multicentre cohort.MethodsThe data from a multicentre psoriatic arthritis database was analysed. Patients were grouped according to age at psoriasis onset (early onset; 40 years of age, late-onset; 40 years of age) and disease characteristics of the groups were compared by adjusting for BMI and PsA duration, where necessary.ResultsAt the time of analyses, 1634 patients were recruited [62.8% females; early onset 1108 (67.8%); late-onset, 526 (32.2%)]. The late-onset group was more over-weight [66.8% vs. 86.8%, p<0.001; adjusted for age -aOR 1.55 (1.11-2.20; 95% CI)]. The early onset group had more scalp psoriasis at onset (56.7% vs. 43.0%, p<0.001), whereas extremity lesions were more common in the late-onset group (63.8% vs. 74.2%, p<0.001). Axial disease in males and psoriatic disease family history in females were significantly higher in the early onset group [38.0% vs. 25.4%; p=0.005; adjusted for PsA duration -aOR 1.76 (1.19-2.62; 95% CI) / 39.5% vs. 30.1%; p=0.003; OR 1.51 (1.15-1.99; 95% CI), respectively]. Psoriatic disease activity parameters, patient-physician reported outcomes and HAQ-DI scores were similar in both groups.ConclusionClinical features of PsA may be affected by the age at onset of PsO. Different genetic backgrounds in early and late-onset PsO may be driving the differences in psoriasis and PsA phenotypes.
  • Publication
    Malignancy risk in systemic lupus erythematosus patients treated with cyclophosphamide
    (Clinical & Exper Rheumatology, 2015-05-01) Yilmaz, N.; Emmungil, H.; Gücenmez, S.; Özen, G.; Yıldız, F.; Balkarlı, A.; Kimyon, G.; Coşkun, B. Necdet; Doğan, I.; Pamuk, O. N.; Yaşar, S.; Cetin, G. Yildirim; Yazıcı, A.; Esmen, S. Ergülü; Cağatay, Y.; Yılmaz, S.; Celle, A.; Cefle, A.; Sayarhoğlu, M.; Kaşifoğlu, T.; Karadağ, O.; Pehlivan, Yavuz; Dalkılıç, Ediz; Kısacık, B.; Cobankara, V.; Erken, E.; Direskeneli, H.; Aksu, K.; Yavuz, S.; COŞKUN, NEJDET; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; Romatoloji Bölümü; 0000-0003-0298-4157; ETE-5180-2022; AAG-8227-2021; AAG-7155-2021
  • Publication
    Predictors for the risk and severity of post-thrombotic syndrome in vascular Behcet's disease
    (Elsevier, 2021-02-04) Aksoy, Aysun; Çolak, Seda; Yağız, Burcu; Coşkun, Belkıs Nihan; Omma, Ahmet; Yıldız, Yasin; Sarı, Alper; Ataş, Nuh; Ilgın, Can; Karadağ, Ömer; Erden, Abdulsamet; Dalkılıç, Ediz; Bolca, Naile; Ergelen, Rabia; Onur, Mehmet Ruhi; Direskeneli, Haner; Alibaz-Öner, Fatma; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; BOLCA TOPAL, NAİLE; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; Romatoloji Bilim Dalı; 0000-0003-0298-4157; JQW-5031-2023; AAG-7155-2021; CMF-4757-2022 ; EKW-9201-2022
    Objective: Deep vein thrombosis (DVT) of the lower extremities is the most common form of vascular involvement in Behcet disease (BD), frequently leading to post-thrombotic syndrome (PTS) as a disabling complication. We have described the clinical characteristics and predictors of PTS presence among patients with BD and lower extremity DVT. We also used venous Doppler ultrasound (US) examinations in our assessment. Methods: Patients with BD (n = 205; 166 men, 39 women; age 39 6 9.5 years) and a history of DVT were investigated. The Villalta scale was used to assess the presence and severity of PTS. Doppler US examinations were performed within 1 week of the clinical evaluation. The total number of vessels with reflux, thrombi, recanalization, and collateral vessels were calculated. Results: Of the 205 patients with BD, 62% had had PTS and 18% had had severe PTS. Patients with PTS had had greater reflux (P = .054) and thrombosis (P = .02) scores compared with patients without PTS. Treatment with anticoagulation (AC), immunosuppressive (IS) therapy, or AC combined with IS drugs did not affect the occurrence of PTS. However, patients treated with IS therapy, with or without AC drugs, had a decreased incidence of severe PTS compared with the AC-only group (P = .017). Patients treated with AC plus IS agents also had increased collateral scores compared with patients treated with only IS drugs. Interferon-a use seemed to provide better recanalization scores compared with azathioprine only (1.0 [range, 0-14] vs 2.5 [range, 0-10]; P = .010). Conclusions: Patients with BD and DVT have a high risk of developing severe PTS. IS treatment decreases the development of severe PTS. AC therapy might influence the course of PTS by increasing the collateral scores, and the use of interferon-a also increased recanalization scores. Routine assessment with Doppler US examinations could be helpful in the prediction of severe PTS.
  • Publication
    Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
    (TÜBİTAK, 2021-01-01) Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Karadağ, Ömer; Dalkılıç, Ediz; Ertenli, Ali İhsan; Kılıç, Levent; Ersözlü, Duygu; Beş, Cemal; Emmungil, Hakan; Mercan, Rıdvan; Ediboğlu, Elif Durak; Kanıtez, Nilüfer; Bilgin, Emre; Çolak, Seda; Koca, Süleyman Serdar; Gönüllü, Emel; Küçükşahin, Orhan; Coşkun, Nihan; Yağız, Burcu; Kiraz, Sedat; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; 0000-0002-3734-1242; 0000-0003-1372-1555; 0000-0001-5184-4404; 0000-0003-1185-5816; 0000-0002-2260-4660; 0000-0003-4995-430X; 0000-0002-6990-4206; W-7332-2019; AAK-7851-2021; AAD-5448-2019; AAZ-5845-2021; AAG-8227-2021; C-8092-2015; JQW-5031-2023; GZA-3287-2022
    Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.
  • Publication
    The effect of rheumatoid factor and anti-cyclic citrullinated peptide positivity on drug survival of abatacept in patients with rheumatoid arthritis in routine care: The results from turkbio registry
    (Wiley, 2015-10-01) Ertenli, İhsan; Karadağ, Ömer; Pehlivan, Yavuz; Dalkılıç, Ediz; Onat, Ahmet Mesut; Kısacık, Bünyamin; Can, Gerçek; Akar, Servet; Çapar, Sedat; Kalyoncu, Ümut; Öksüz, Mustafa Ferhat; Tarhan, Emine Figen; Akkoç, Nurullah; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Oksuz, Mustafa Ferhat; Tıp Fakültesi; Romatoloji Ana Bilim Dalı; AAG-8227-2021; CMF-4757-2022; JXF-7598-2024
  • Publication
    Dose escalation and switching patterns of anti-tnf drugs in rheumatoid arthritis: A retrospective chart - review study in Turkey
    (Bmj Publishing Group, 2015-06-01) Kalyoncu, U.; Aydın, S. Z.; Dalkılıç, E.; Kaşifoğlu, T.; Kısacık, B.; Pamuk, O. N.; Yılmaz, S.; Yazıcı, A.; Yazısız, V.; Koca, S. S.; Öksüz, Mustafa Ferhat; DALKILIÇ, HÜSEYİN EDİZ; Öksüz, Mustafa Ferhat; Romatoloji Bölümü; CMF-4757-2022; KQP-2558-2024